Alpha-1 antitrypsin (AAT) and alpha-2 macroglobulin (AMG) levels according to the stages and histological types in lung cancer

M. Gassaloglu, I. Karasu, A. Ozsoz, G. Senol (Izmir, Turkey)

Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Session: Biology and prognosis in thoracic oncology
Session type: Thematic Poster Session
Number: 2609
Disease area: Thoracic oncology

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Gassaloglu, I. Karasu, A. Ozsoz, G. Senol (Izmir, Turkey). Alpha-1 antitrypsin (AAT) and alpha-2 macroglobulin (AMG) levels according to the stages and histological types in lung cancer. Eur Respir J 2008; 32: Suppl. 52, 2609

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD).
Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases
Year: 2021


Intra-epithelial polymerization, accumulation and secretion of alpha1 antitrypsin (AAT) Z polymers in the lung of patients with alpha-1 antitrypsin deficiency (AATD)
Source: Annual Congress 2010 - Epithelial cell biology
Year: 2010



A high purity alpha-1 antitrypsin (AAT) from human plasma, TAL6004
Source: Annual Congress 2009 - Treatment of airways disease
Year: 2009


Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD)
Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Year: 2018


Regional deposition of 99mTc-labelled alpha-1 antitrypsin (AAT) in patients with alpha-1 antitrypsin deficiency and cystic fibrosis (CF) compared with healthy volunteers
Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects
Year: 2007


The results of alpha-1 antitrypsine (AAT) phenotyping in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 260s
Year: 2002

Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis
Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD
Year: 2008

Alpha-1 antitrypsin (AAT) polymerization in alveolar macrophages of AAT deficient individuals and in smokers.
Source: International Congress 2017 – New Mechanistic Findings in COPD
Year: 2017

Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011


Alpha 1 antitrypsin (A1AT) deficiency among patients with cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 501s
Year: 2003

LSC - 2017 - The serum levels of alpha-1 antitrypsin are strongly associated with its local production by NSCLC tumor cells
Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors
Year: 2017

Screening for alpha-1 antitrypsin deficiency in Polish lung or liver disease patients
Source: Annual Congress 2011 - Lung development and neoplasia
Year: 2011

Alpha-1 antitrypsin: functional analysis of novel variants
Source: Research Seminar 2014 - Protein quality control in lung disease
Year: 2014


Alpha 1 - antitrypsin deficiency: diagnosis and treatment
Source: Virtual Congress 2021 – Alpha 1 - antitrypsin deficiency: diagnosis and treatment
Year: 2021

Functional alterations of small airways in patients with alpha-1 antitrypsin deficiency (AATD) in a longitudinal study
Source: Eur Respir J 2005; 26: Suppl. 49, 361s
Year: 2005

Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease.
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019


Effect of serum alpha-1-antitrypsin (AAT) and alpha-2-macroglobulin (AMG) levels on sputum conversion in active pulmonary tuberculosis
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III
Year: 2008


Serum TNFα, CD14 and CRP levels in COPD patients with different alpha-1 antitrypsin phenotypes
Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases
Year: 2008


Alpha 1 antitrypsin (A1AT) deficiency in children with asthma in Brazil
Source: Eur Respir J 2003; 22: Suppl. 45, 499s
Year: 2003

Exercise intolerance and lung emphysema in alpha-1 antitrypsin deficiency (AATD)
Source: Annual Congress 2010 - Exercise in COPD
Year: 2010